Suppr超能文献

疑似急性心肌梗死患者中影响游离(未结合)利多卡因浓度的因素。

Factors affecting free (unbound) lignocaine concentration in suspected acute myocardial infarction.

作者信息

Routledge P A, Stargel W W, Barchowsky A, Wagner G S, Shand D G

机构信息

Division of Clinical Pharmacology, Duke University Medical Center, Durham, NC.

出版信息

Br J Clin Pharmacol. 1989 Nov;28(5):593-7. doi: 10.1111/j.1365-2125.1989.tb03547.x.

Abstract
  1. Free plasma lignocaine concentrations were measured for up to 48 h after constant infusion of the drug in 41 subjects with suspected acute myocardial infarction. 2. The free plasma lignocaine clearance at 12 h was significantly and proportionately related to body weight and to the presence of mild (Killip Class II) heart failure, with an 18% reduction in free clearance in the latter condition. 3. The free plasma lignocaine was not related to sex, age or the presence of confirmed acute myocardial infarction, when corrected for the effects of body weight and presence of heart failure. 4. Free plasma lignocaine concentration 1 h after a fixed loading dose were also significantly related to body weight and presence of heart failure but not to sex, age or proven acute myocardial infarction. 5. The data indicate that correction of loading and maintenance infusion for body weight and presence of (even mild) heart failure should somewhat reduce variability in free (and presumably active) plasma lignocaine concentrations but that the free plasma lignocaine concentration at 12 h is most accurately predicted by measuring the free (and to a lesser extent total) plasma lignocaine concentration at 1 h.
摘要
  1. 对41名疑似急性心肌梗死患者持续输注药物后,测定长达48小时的血浆游离利多卡因浓度。2. 12小时时的血浆游离利多卡因清除率与体重以及轻度(Killip分级II级)心力衰竭的存在显著且成比例相关,在后一种情况下游离清除率降低18%。3. 在校正体重和心力衰竭存在的影响后,血浆游离利多卡因与性别、年龄或确诊的急性心肌梗死无关。4. 固定负荷剂量给药1小时后的血浆游离利多卡因浓度也与体重和心力衰竭的存在显著相关,但与性别、年龄或已证实的急性心肌梗死无关。5. 数据表明,根据体重和(即使是轻度)心力衰竭的存在来校正负荷剂量和维持输注,应能在一定程度上降低血浆游离(可能是活性)利多卡因浓度的变异性,但通过测量1小时时的血浆游离(以及在较小程度上总)利多卡因浓度能最准确地预测12小时时的血浆游离利多卡因浓度。

相似文献

1
Factors affecting free (unbound) lignocaine concentration in suspected acute myocardial infarction.
Br J Clin Pharmacol. 1989 Nov;28(5):593-7. doi: 10.1111/j.1365-2125.1989.tb03547.x.
2
Impaired Lignocaine metabolism in patients with myocardial infarction and cardiac failure.
Br Med J. 1976 Apr 17;1(6015):939-41. doi: 10.1136/bmj.1.6015.939.
3
The pharmacokinetics of lignocaine and beta-adrenoceptor antagonists in patients with acute myocardial infarction.
Clin Pharmacokinet. 1987 Nov;13(5):293-316. doi: 10.2165/00003088-198713050-00002.
4
Clinical pharmacokinetics of lignocaine.
Clin Pharmacokinet. 1978 May-Jun;3(3):177-201. doi: 10.2165/00003088-197803030-00001.
6
Relation between plasma lignocaine levels and induced haemodynamic changes.
Br Med J. 1969 Aug 16;3(5667):390-2. doi: 10.1136/bmj.3.5667.390.
7
Age-dependent lidocaine disposition in patients with acute myocardial infarction.
Clin Pharmacol Ther. 1985 Apr;37(4):381-6. doi: 10.1038/clpt.1985.58.
8
A free lignocaine index as a guide to unbound drug concentration.
Br J Clin Pharmacol. 1985 Dec;20(6):695-8. doi: 10.1111/j.1365-2125.1985.tb05132.x.
9
On the role of alpha 1-acid glycoprotein in lignocaine accumulation following myocardial infarction.
Br J Clin Pharmacol. 1982 Mar;13(3):411-5. doi: 10.1111/j.1365-2125.1982.tb01394.x.
10
Logical approach to lignocaine therapy.
Br Med J. 1976 Jan 3;1(6000):13-5. doi: 10.1136/bmj.1.6000.13.

引用本文的文献

1
Pharmacokinetics of Intraperitoneal Lidocaine for Sustained Postoperative Analgesia in Adults.
Eur J Drug Metab Pharmacokinet. 2025 May 8. doi: 10.1007/s13318-025-00948-1.
2
Nonlinear pharmacokinetics: clinical Implications.
Clin Pharmacokinet. 1991 Jun;20(6):429-46. doi: 10.2165/00003088-199120060-00001.

本文引用的文献

1
Relationship between alpha 1-acid glycoprotein and lidocaine disposition in myocardial infarction.
Clin Pharmacol Ther. 1981 Aug;30(2):154-7. doi: 10.1038/clpt.1981.141.
2
A comparison of methods of lidocaine administration in patients.
Clin Pharmacol Ther. 1981 May;29(5):617-24. doi: 10.1038/clpt.1981.86.
3
Increased alpha-1-acid glycoprotein and lidocaine disposition in myocardial infarction.
Ann Intern Med. 1980 Nov;93(5):701-4. doi: 10.7326/0003-4819-93-5-701.
4
Control of lidocaine therapy: new perspectives.
Ther Drug Monit. 1982;4(3):265-70. doi: 10.1097/00007691-198208000-00003.
5
On the role of alpha 1-acid glycoprotein in lignocaine accumulation following myocardial infarction.
Br J Clin Pharmacol. 1982 Mar;13(3):411-5. doi: 10.1111/j.1365-2125.1982.tb01394.x.
6
Impairment of lidocaine clearance in elderly male subjects.
J Cardiovasc Pharmacol. 1983 Nov-Dec;5(6):1093-6. doi: 10.1097/00005344-198311000-00027.
7
Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans.
Ann Intern Med. 1973 Apr;78(4):499-508. doi: 10.7326/0003-4819-78-4-499.
8
Impaired Lignocaine metabolism in patients with myocardial infarction and cardiac failure.
Br Med J. 1976 Apr 17;1(6015):939-41. doi: 10.1136/bmj.1.6015.939.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验